Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Cilengitide (Primary)
- Indications Brain cancer; CNS cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 11 Jan 2013 Planned number of patients changed from 18 to 24 as reported by ClinicalTrials.gov.
- 11 Jan 2013 Actual end date changed from Mar 2008 to Jul 2006 as reported by ClinicalTrials.gov.